This episode delves into the critical question of seizure prophylaxis in patients undergoing glioma surgery. We review findings from the SPRING Randomized Controlled Trial (RCT), as summarized in an abstract published in Health Technology Assessment in 2026. The study examines the current practice of perioperative antiseizure medication use in seizure-naive glioma patients despite a lack of routine guideline recommendation, focusing on the frequency and potential effectiveness of drugs like levetiracetam. Discussions will highlight the implications for clinical decision-making, addressing the balance between potential benefits and risks in this patient population. This content is for informational purposes only and is not a substitute for professional medical advice. Any medical decisions should be made in consultation with a qualified healthcare provider.